Terming the new year to be a make-or-break one for Sun Pharma, CLSA believes that specialty pipeline will be a key focus area.
In India, it said, Sun Pharma would aim to outperform industry growth after a weak CY2018.
Analysts at the firm expect the company to remain acquisitive towards specialty products.
Stock valuation is attractive and stronger specialty portfolio ramp up could drive re-rating.
The brokerage has a buy call on the stock with a target at Rs 560.
We provide you sure shot Commodity & Equity Market Tips, Intraday tips, share market tips, Mcx bullion tips, Mcx tips, Crude tips, Stock tips, Future and Cash tips with Technical & Fundamental Research.
Visit: www.ripplesadvisory.com
Contact us @ +91-9644405056
No comments:
Post a Comment